dc.contributor.author | Skotland, Tore | |
dc.contributor.author | Iversen, Tore Geir | |
dc.contributor.author | Llorente, Alicia | |
dc.contributor.author | Sandvig, Kirsten | |
dc.date.accessioned | 2022-09-30T11:43:07Z | |
dc.date.available | 2022-09-30T11:43:07Z | |
dc.date.created | 2022-07-01T11:54:18Z | |
dc.date.issued | 2022-05-21 | |
dc.identifier.citation | Advanced Drug Delivery Reviews. 2022, 186 1-17. | en_US |
dc.identifier.issn | 0169-409X | |
dc.identifier.issn | 1872-8294 | |
dc.identifier.uri | https://hdl.handle.net/11250/3022893 | |
dc.description.abstract | There is a large interest in developing nanoparticles and extracellular vesicles for delivery of therapeutics or imaging agents. Regulatory approval of such products requires knowledge about their biodistribution, metabolism and excretion. We here discuss possibilities and challenges of methods used for such studies, which most often are performed after labelling with radioactive isotopes or fluorescent molecules. It is important to evaluate if the labelled and unlabeled products can be expected to behave similarly in the body. Furthermore, one needs to critically consider whether the labels are still associated with the product at the time of analyses. We discuss advantages and disadvantages of different imaging modalities such as PET, SPECT, MRI, CT, ultrasound and optical imaging for whole-body biodistribution, and describe how to estimate the amount of labelled product in harvested organs and tissue. Microscopy of cells and tissues and various mass spectrometry methods are also discussed in this review. | en_US |
dc.description.sponsorship | The authors have been supported by the Norwegian Cancer Society, the Research Council of Norway and the South Eastern Norway Regional Health Authority. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartofseries | Advanced Drug Delivery Reviews;Volume 186, July 2022, 114326 | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | Biodegradable substances | en_US |
dc.subject | Cancer therapy | en_US |
dc.subject | Fluorescent labelling | en_US |
dc.subject | Microscopy | en_US |
dc.subject | Nanomedicine | en_US |
dc.subject | Imaging | en_US |
dc.subject | Radioactive labelling | en_US |
dc.title | Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2022 The Authors | en_US |
dc.source.articlenumber | 114326 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | https://doi.org/10.1016/j.addr.2022.114326 | |
dc.identifier.cristin | 2036636 | |
dc.source.journal | Advanced Drug Delivery Reviews | en_US |
dc.source.volume | 186 | en_US |
dc.source.issue | 186 | en_US |
dc.source.pagenumber | 1-17 | en_US |
dc.relation.project | Norges forskningsråd: 228200 | en_US |
dc.relation.project | Kreftforeningen: 208239 | en_US |